IMpact-RSV Study Group report.
Zempsky
W T
WT
Schechter
N L
NL
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007223:Infant; D007273:Injections, Intramuscular / Q000009:adverse effects*; D010146:Pain / Q000209:etiology / Q000517:prevention & control*; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069455:Palivizumab